Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

NCT02314676 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02314676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02314676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
November 30, 2014
Completion date
Not reported
Enrollment
900 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dwarfism, pituitary